Skip to content
LexBuild

New Animal Drugs; Change of Sponsor's Name and Address

---
identifier: "/us/fr/2011-17292"
source: "fr"
legal_status: "authoritative_unofficial"
title: "New Animal Drugs; Change of Sponsor's Name and Address"
title_number: 0
title_name: "Federal Register"
section_number: "2011-17292"
section_name: "New Animal Drugs; Change of Sponsor's Name and Address"
positive_law: false
currency: "2011-07-11"
last_updated: "2011-07-11"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Health and Human Services Department"
document_number: "2011-17292"
document_type: "rule"
publication_date: "2011-07-11"
agencies:
  - "Health and Human Services Department"
  - "Food and Drug Administration"
cfr_references:
  - "21 CFR Part 510"
fr_citation: "76 FR 40612"
fr_volume: 76
docket_ids:
  - "Docket No. FDA-2011-N-0003"
effective_date: "2011-07-11"
fr_action: "Final rule."
---

#  Names, addresses, and drug labeler codes of sponsors of approved applications.

**AGENCY:**

Food and Drug Administration, HHS.

**ACTION:**

Final rule.

**SUMMARY:**

The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor's name from Alpharma, LLC, to Alpharma, LLC, a wholly owned subsidiary of Pfizer, Inc. The sponsor's mailing address will also be changed.

**DATES:**

This rule is effective July 11, 2011.

**FOR FURTHER INFORMATION CONTACT:**

Steven D. Vaughn, Center for Veterinary Medicine (HFV-100), Food and Drug Administration, 7520 Standish Pl., Rockville, MD 20855, 240-276-8300, *e-mail: [email protected].*

**SUPPLEMENTARY INFORMATION:**

Alpharma, LLC, 400 Crossing Blvd., Bridgewater, NJ 08807 has informed FDA of a change of name and mailing address to Alpharma, LLC, a wholly owned subsidiary of Pfizer, Inc., 235 East 42d St., New York, NY 10017. Accordingly, the Agency is amending the regulations in 21 CFR 510.600(c) to reflect these changes.

This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

**List of Subjects in 21 CFR Part 510**

Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 510 is amended as follows:

**21 CFR Part 510**

**PART 510—NEW ANIMAL DRUGS**

1. The authority citation for 21 CFR part 510 continues to read as follows:

**Authority:**

21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

**21 CFR Part 510**

2. In § 510.600, in the table in paragraph (c)(1), revise the entry for “Alpharma LLC”; and in the table in paragraph (c)(2), revise the entry for “046573” to read as follows:

§ 510.600

(c) * * *

(1) * * *

| Firm name and address | Drug labeler code |
| --- | --- |
|  |  |
| *    *    *    *    * |  |
| Alpharma, LLC, a wholly owned subsidiary of Pfizer, Inc., 235 East 42d St., New York, NY 10017 | 046573 |
|  |  |
| *    *    *    *    * |  |

(2) * * *

| Drug labeler code | Firm name and address |
| --- | --- |
|  |  |
| *    *    *    *    * |  |
| 046573 | Alpharma, LLC, a wholly owned subsidiary of Pfizer, Inc., 235 East 42d St., New York, NY 10017 |
|  |  |
| *    *    *    *    * |  |

Dated: July 1, 2011.

Elizabeth Rettie,

Deputy Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.